Of the 808,000 dialysis patients in the US,60% have diabetes and are potentially eligible for glucagon-like peptide-1 (GLP-1) receptor agonist treatment. Their safety and outcomes in this population is unknown. The objective of this study was to examine GLP-1 receptor agonist real-world safety,efficacy,and weight loss extent in people with diabetes on dialysis.
PDF的下载单位、IP信息已删除
(2025-6-4)
DW
老的火龙果
无极微光
秋风
OK
xing_xing
Nole
aaaa
cdercder
贪玩的秋柔
coolru
aajhajkahna
DOC_XIONG
Enigma_GEB
Ali
Kao
七听
JIE
李杰杰
Criminology34
皖公网安备34019202002308
